SNN vs WST
Smith & Nephew plc vs West Pharmaceutical Services — AI-powered side-by-side comparison
SNN
Smith & Nephew plc
59
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | SNN | WST |
|---|
| AI Score |
59
|
74
|
| Price |
$30.05
|
$351.74
|
| P/E Ratio |
19.70×
|
44.65×
|
| ROE |
11.8%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.2%
|
36.8%
|
| Debt / Equity |
0.73×
|
0.10×
|
| Dividend Yield |
2.6%
|
0.3%
|
| RSI (14) |
40.7
|
58.0
|
| Beta |
0.688
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for SNN versus WST.
WST leads by 15 points.
WST scores 74/100 (Buy) versus SNN at 59/100 (Watch).
SNN Committee View
40% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Technical Analyst remains cautious — price structure making lower highs and lower lows. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Dividend yield of 2.7% pays you to wait — Value
- EPS growing 52.3% YoY — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical